Jia Wang1,2,3, Zhao Cui4,2,3, Jie Lu5, Christian Probst6, Yi-Miao Zhang1,2,3, Xin Wang1,2,3, Zhen Qu1,2,3, Fang Wang1,2,3, Li-Qiang Meng1,2,3, Xu-Yang Cheng1,2,3, Gang Liu1,2,3, Hanna Debiec7,8, Pierre Ronco7,8,9, Ming-Hui Zhao1,2,3,10. 1. Renal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University. 2. Key Laboratory of Renal Disease and. 3. Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China. 4. Renal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University; cuizhao@bjmu.edu.cn. 5. Euroimmun Academy, Euroimmun Medical Diagnostics (China) Co., Ltd., Beijing, China. 6. Institute of Experimental Immunology, Euroimmun Academy, Euroimmun Medical Diagnostics Co., Ltd Lubeck, Germany. 7. Department of Nephrology and Dialysis, Pierre and Marie Curie University, Paris Cedex 06, France. 8. Department of Nephrology and Dialysis, National Institute for Health and Medical Research, 1155, Paris, France. 9. Assistance publique - Hôpitaux de Paris, Service de Néphrologie et Dialyses, Hôpital Tenon, Paris, France; and. 10. Peking-Tsinghua Center for Life Sciences, Beijing, China.
Abstract
BACKGROUND AND OBJECTIVES: Thrombospondin type-I domain-containing 7A (THSD7A) was recently identified as the target antigen in about 10% of patients with M-type phospholipase A2 receptor (PLA2R)-negative membranous nephropathy in European and North American populations. The prevalence of THSD7A in other populations and their clinical associations deserve further clarification. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Immunofluorescence assay was performed to investigate anti-THSD7A antibodies in 578 consecutive patients with biopsy-proven idiopathic membranous nephropathy, 114 patients with secondary membranous nephropathy, 64 disease controls, and 20 healthy controls. Glomerular expression of THSD7A antigen was examined by immunohistochemistry. Anti-PLA2R antibodies and glomerular PLA2R expression were also screened. RESULTS: Among the 578 patients with idiopathic membranous nephropathy, 12 (2%) patients were identified as THSD7A-positive: ten patients were THSD7A-positive alone, which accounted for 16% (ten of 64) of PLA2R-negative patients; two patients were dual-positive for both anti-THSD7A and anti-PLA2R antibodies and showed enhanced expression of both antigens colocalized in glomeruli. Among the 114 patients with secondary membranous nephropathy, one among 44 (2%) patients with cancer had anti-THSD7A antibodies, whereas 18 of 44 (41%) had anti-PLA2R antibodies. No anti-THSD7A antibody was detected in other disease controls or healthy individuals. Clinical features were comparable between the patients with and without THSD7A. During follow-up, two patients who achieved remission had a clearance of circulating antibodies against THSD7A, whereas antibodies increased in parallel with proteinuria in a patient with a relapse. CONCLUSIONS: THSD7A-associated membranous nephropathy has a low prevalence in Chinese patients. The double-positive patients suggest dual autoimmune responses.
BACKGROUND AND OBJECTIVES: Thrombospondin type-I domain-containing 7A (THSD7A) was recently identified as the target antigen in about 10% of patients with M-type phospholipase A2 receptor (PLA2R)-negative membranous nephropathy in European and North American populations. The prevalence of THSD7A in other populations and their clinical associations deserve further clarification. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Immunofluorescence assay was performed to investigate anti-THSD7A antibodies in 578 consecutive patients with biopsy-proven idiopathic membranous nephropathy, 114 patients with secondary membranous nephropathy, 64 disease controls, and 20 healthy controls. Glomerular expression of THSD7A antigen was examined by immunohistochemistry. Anti-PLA2R antibodies and glomerular PLA2R expression were also screened. RESULTS: Among the 578 patients with idiopathic membranous nephropathy, 12 (2%) patients were identified as THSD7A-positive: ten patients were THSD7A-positive alone, which accounted for 16% (ten of 64) of PLA2R-negative patients; two patients were dual-positive for both anti-THSD7A and anti-PLA2R antibodies and showed enhanced expression of both antigens colocalized in glomeruli. Among the 114 patients with secondary membranous nephropathy, one among 44 (2%) patients with cancer had anti-THSD7A antibodies, whereas 18 of 44 (41%) had anti-PLA2R antibodies. No anti-THSD7A antibody was detected in other disease controls or healthy individuals. Clinical features were comparable between the patients with and without THSD7A. During follow-up, two patients who achieved remission had a clearance of circulating antibodies against THSD7A, whereas antibodies increased in parallel with proteinuria in a patient with a relapse. CONCLUSIONS: THSD7A-associated membranous nephropathy has a low prevalence in Chinese patients. The double-positive patients suggest dual autoimmune responses.
Authors: Barbora Svobodova; Eva Honsova; Pierre Ronco; Vladimir Tesar; Hanna Debiec Journal: Nephrol Dial Transplant Date: 2012-12-06 Impact factor: 5.992
Authors: Laurence H Beck; Ramon G B Bonegio; Gérard Lambeau; David M Beck; David W Powell; Timothy D Cummins; Jon B Klein; David J Salant Journal: N Engl J Med Date: 2009-07-02 Impact factor: 91.245
Authors: Li Lin; Wei Ming Wang; Xiao Xia Pan; Jing Xu; Chen Ni Gao; Wen Zhang; Hong Ren; Jing Yuan Xie; Pin Yan Shen; Yao Wen Xu; Li Yan Ni; Nan Chen Journal: Oncotarget Date: 2016-10-18
Authors: Larissa Seifert; Elion Hoxha; Anna M Eichhoff; Gunther Zahner; Silke Dehde; Linda Reinhard; Friedrich Koch-Nolte; Rolf A K Stahl; Nicola M Tomas Journal: J Am Soc Nephrol Date: 2018-03-19 Impact factor: 10.121
Authors: Agnieszka Pozdzik; Isabelle Brochériou; Cristina David; Fahd Touzani; Jean Michel Goujon; Karl Martin Wissing Journal: Biomed Res Int Date: 2018-01-08 Impact factor: 3.411